The cell & gene therapy manufacturing services market size has grown rapidly in recent years. It will grow from $9.44 billion in 2025 to $11.08 billion in 2026 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to increasing number of cell and gene therapy clinical candidates, early outsourcing of manufacturing services, expansion of academic translational research, limited in-house manufacturing capabilities, growing demand for specialized bioprocessing.
The cell & gene therapy manufacturing services market size is expected to see rapid growth in the next few years. It will grow to $21.05 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to increasing commercialization of cell and gene therapies, rising demand for large-scale manufacturing services, expansion of personalized medicine pipelines, increasing regulatory clarity for advanced therapies, growing investments in advanced therapy infrastructure. Major trends in the forecast period include expansion of gmp-compliant manufacturing capacity, growing adoption of automated cell processing systems, rising demand for scalable viral vector production, increasing integration of advanced quality control technologies, enhanced focus on manufacturing standardization.
The increasing prevalence of cancer and other target diseases is expected to drive the growth of the cell and gene therapy manufacturing services market in the coming years. Cancer is a serious condition in which the body’s cells grow rapidly and uncontrollably, leading to abnormal tissue development. Cell and gene therapies are emerging as promising approaches to address the rising rates of cancer, fueling the demand for innovative and effective treatment options. For example, in February 2025, the American Cancer Society, a US-based nonprofit organization focused on cancer advocacy, estimated that in the US, 316,950 new cases of invasive breast cancer will be diagnosed in women and 2,800 cases in men. Consequently, the growing prevalence of cancer and other target diseases is propelling the expansion of the cell and gene therapy manufacturing services market.
Major companies in the cell and gene therapy manufacturing services market are concentrating on developing advanced biomanufacturing technologies to improve scalability, production efficiency, and the overall quality of cell and gene therapies. For example, in September 2025, ARPA-H, a US-based government health agency, launched a program to stimulate innovative biomanufacturing for cell and gene therapies. The program is designed to accelerate the creation of advanced manufacturing platforms, enhance production yields, and enable cost-effective, scalable production of complex cell and gene therapy products. By supporting high-risk, high-reward technologies, the initiative is expected to foster innovation in biomanufacturing, strengthen the manufacturing ecosystem, and enable quicker patient access to transformative therapies.
In June 2024, Genezen, a U.S.-based gene and cell therapy company, acquired UniQure for an undisclosed amount. Through this acquisition, Genezen aims to strengthen its gene therapy production capabilities, broaden its service portfolio, and utilize UniQure's expertise to address the increasing demand for innovative gene therapies in the market. UniQure is a Netherlands-based biotechnology company focused on developing gene therapies for serious diseases.
Major companies operating in the cell & gene therapy manufacturing services market are Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Fujifilm Holdings Corporation, Oxford Biomedica plc, Cell and Gene Therapy Catapult, Samsung Biologics Co. Ltd., BioNTech SE, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Sarepta Therapeutics Inc., bluebird bio Inc., Precision BioSciences Inc., GSK plc, AstraZeneca plc, Bayer AG.
North America was the largest region in the cell and gene therapy manufacturing services market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global cell & gene therapy manufacturing services market report forecast period. The regions covered in the cell & gene therapy manufacturing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell & gene therapy manufacturing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cell and gene therapy manufacturing services market by raising costs of imported bioreactors, single-use consumables, analytical instruments, and cold-chain equipment essential for production and testing. Service providers in North America and Europe are most affected due to reliance on specialized imported manufacturing tools, while Asia-Pacific faces cost pressures on exported manufacturing services. These tariffs are increasing operational expenses and service pricing. At the same time, they are encouraging domestic equipment manufacturing, localized supply chains, and capacity expansion within regional advanced therapy manufacturing hubs.
The cell & gene therapy manufacturing services market research report is one of a series of new reports that provides cell & gene therapy manufacturing services market statistics, including cell & gene therapy manufacturing services industry global market size, regional shares, competitors with a cell & gene therapy manufacturing services market share, detailed cell & gene therapy manufacturing services market segments, market trends and opportunities, and any further data you may need to thrive in the cell & gene therapy manufacturing services industry. This cell & gene therapy manufacturing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell and gene therapy manufacturing services encompass the production and quality-testing of gene and cell therapy products. They support the development and manufacturing of treatments for degenerative diseases, tissue damage, and genetic disorders. These services cover good manufacturing practices, ancillary reagents, flow cytometry, immunoassays, and gene engineering solutions.
The primary types of cell and gene therapy manufacturing services include gene therapy and cell therapy. Gene therapy is a medical approach that targets the root genetic cause to treat or prevent diseases. These services are applied in both commercial and clinical manufacturing for various conditions, including central nervous system disorders, ophthalmologic diseases, cardiovascular diseases, infectious diseases, orthopedic conditions, and oncology. They are utilized by academic and research institutions, pharmaceutical and biotechnology companies, and other organizations.
The cell and gene therapy manufacturing services market includes revenues earned by cell and gene therapy manufacturing and related services which include analytical and process development, current good manufacturing practice cell therapy manufacturing services of autologous and allogeneic t-cells, natural killer cells, dendritic cells, mesenchymal stem cells, hematopoietic stem cells, and more. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell & gene therapy manufacturing services market size is expected to see rapid growth in the next few years. It will grow to $21.05 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to increasing commercialization of cell and gene therapies, rising demand for large-scale manufacturing services, expansion of personalized medicine pipelines, increasing regulatory clarity for advanced therapies, growing investments in advanced therapy infrastructure. Major trends in the forecast period include expansion of gmp-compliant manufacturing capacity, growing adoption of automated cell processing systems, rising demand for scalable viral vector production, increasing integration of advanced quality control technologies, enhanced focus on manufacturing standardization.
The increasing prevalence of cancer and other target diseases is expected to drive the growth of the cell and gene therapy manufacturing services market in the coming years. Cancer is a serious condition in which the body’s cells grow rapidly and uncontrollably, leading to abnormal tissue development. Cell and gene therapies are emerging as promising approaches to address the rising rates of cancer, fueling the demand for innovative and effective treatment options. For example, in February 2025, the American Cancer Society, a US-based nonprofit organization focused on cancer advocacy, estimated that in the US, 316,950 new cases of invasive breast cancer will be diagnosed in women and 2,800 cases in men. Consequently, the growing prevalence of cancer and other target diseases is propelling the expansion of the cell and gene therapy manufacturing services market.
Major companies in the cell and gene therapy manufacturing services market are concentrating on developing advanced biomanufacturing technologies to improve scalability, production efficiency, and the overall quality of cell and gene therapies. For example, in September 2025, ARPA-H, a US-based government health agency, launched a program to stimulate innovative biomanufacturing for cell and gene therapies. The program is designed to accelerate the creation of advanced manufacturing platforms, enhance production yields, and enable cost-effective, scalable production of complex cell and gene therapy products. By supporting high-risk, high-reward technologies, the initiative is expected to foster innovation in biomanufacturing, strengthen the manufacturing ecosystem, and enable quicker patient access to transformative therapies.
In June 2024, Genezen, a U.S.-based gene and cell therapy company, acquired UniQure for an undisclosed amount. Through this acquisition, Genezen aims to strengthen its gene therapy production capabilities, broaden its service portfolio, and utilize UniQure's expertise to address the increasing demand for innovative gene therapies in the market. UniQure is a Netherlands-based biotechnology company focused on developing gene therapies for serious diseases.
Major companies operating in the cell & gene therapy manufacturing services market are Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Fujifilm Holdings Corporation, Oxford Biomedica plc, Cell and Gene Therapy Catapult, Samsung Biologics Co. Ltd., BioNTech SE, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Sarepta Therapeutics Inc., bluebird bio Inc., Precision BioSciences Inc., GSK plc, AstraZeneca plc, Bayer AG.
North America was the largest region in the cell and gene therapy manufacturing services market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global cell & gene therapy manufacturing services market report forecast period. The regions covered in the cell & gene therapy manufacturing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell & gene therapy manufacturing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cell and gene therapy manufacturing services market by raising costs of imported bioreactors, single-use consumables, analytical instruments, and cold-chain equipment essential for production and testing. Service providers in North America and Europe are most affected due to reliance on specialized imported manufacturing tools, while Asia-Pacific faces cost pressures on exported manufacturing services. These tariffs are increasing operational expenses and service pricing. At the same time, they are encouraging domestic equipment manufacturing, localized supply chains, and capacity expansion within regional advanced therapy manufacturing hubs.
The cell & gene therapy manufacturing services market research report is one of a series of new reports that provides cell & gene therapy manufacturing services market statistics, including cell & gene therapy manufacturing services industry global market size, regional shares, competitors with a cell & gene therapy manufacturing services market share, detailed cell & gene therapy manufacturing services market segments, market trends and opportunities, and any further data you may need to thrive in the cell & gene therapy manufacturing services industry. This cell & gene therapy manufacturing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell and gene therapy manufacturing services encompass the production and quality-testing of gene and cell therapy products. They support the development and manufacturing of treatments for degenerative diseases, tissue damage, and genetic disorders. These services cover good manufacturing practices, ancillary reagents, flow cytometry, immunoassays, and gene engineering solutions.
The primary types of cell and gene therapy manufacturing services include gene therapy and cell therapy. Gene therapy is a medical approach that targets the root genetic cause to treat or prevent diseases. These services are applied in both commercial and clinical manufacturing for various conditions, including central nervous system disorders, ophthalmologic diseases, cardiovascular diseases, infectious diseases, orthopedic conditions, and oncology. They are utilized by academic and research institutions, pharmaceutical and biotechnology companies, and other organizations.
The cell and gene therapy manufacturing services market includes revenues earned by cell and gene therapy manufacturing and related services which include analytical and process development, current good manufacturing practice cell therapy manufacturing services of autologous and allogeneic t-cells, natural killer cells, dendritic cells, mesenchymal stem cells, hematopoietic stem cells, and more. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell & Gene Therapy Manufacturing Services Market Characteristics
3. Cell & Gene Therapy Manufacturing Services Market Supply Chain Analysis
4. Global Cell & Gene Therapy Manufacturing Services Market Trends and Strategies
5. Cell & Gene Therapy Manufacturing Services Market Analysis of End Use Industries
7. Global Cell & Gene Therapy Manufacturing Services Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell & Gene Therapy Manufacturing Services Total Addressable Market (TAM) Analysis for the Market
9. Cell & Gene Therapy Manufacturing Services Market Segmentation
10. Cell & Gene Therapy Manufacturing Services Market Regional and Country Analysis
11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market
12. China Cell & Gene Therapy Manufacturing Services Market
13. India Cell & Gene Therapy Manufacturing Services Market
14. Japan Cell & Gene Therapy Manufacturing Services Market
15. Australia Cell & Gene Therapy Manufacturing Services Market
16. Indonesia Cell & Gene Therapy Manufacturing Services Market
17. South Korea Cell & Gene Therapy Manufacturing Services Market
18. Taiwan Cell & Gene Therapy Manufacturing Services Market
19. South East Asia Cell & Gene Therapy Manufacturing Services Market
20. Western Europe Cell & Gene Therapy Manufacturing Services Market
21. UK Cell & Gene Therapy Manufacturing Services Market
22. Germany Cell & Gene Therapy Manufacturing Services Market
23. France Cell & Gene Therapy Manufacturing Services Market
24. Italy Cell & Gene Therapy Manufacturing Services Market
25. Spain Cell & Gene Therapy Manufacturing Services Market
26. Eastern Europe Cell & Gene Therapy Manufacturing Services Market
27. Russia Cell & Gene Therapy Manufacturing Services Market
28. North America Cell & Gene Therapy Manufacturing Services Market
29. USA Cell & Gene Therapy Manufacturing Services Market
30. Canada Cell & Gene Therapy Manufacturing Services Market
31. South America Cell & Gene Therapy Manufacturing Services Market
32. Brazil Cell & Gene Therapy Manufacturing Services Market
33. Middle East Cell & Gene Therapy Manufacturing Services Market
34. Africa Cell & Gene Therapy Manufacturing Services Market
36. Cell & Gene Therapy Manufacturing Services Market Competitive Landscape and Company Profiles
37. Cell & Gene Therapy Manufacturing Services Market Other Major and Innovative Companies
40. Cell & Gene Therapy Manufacturing Services Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cell & Gene Therapy Manufacturing Services Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell & gene therapy manufacturing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell & gene therapy manufacturing services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell & gene therapy manufacturing services market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Gene Therapy; Cell Therapy2) By Indication: Central Nervous System Disorders; Ophthalmology Diseases; Cardiovascular Diseases; Infectious Diseases; Orthopedic Diseases; Oncology Diseases
3) By Application: Commercial Manufacturing; Clinical Manufacturing
4) By End-user: Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Gene Therapy: Viral Vector Manufacturing; Plasmid DNA Production; Gene Editing Services; Formulation And Fill-Finish Services2) By Cell Therapy: Cell Sourcing And Banking; Cell Processing And Expansion; Quality Control And Testing Services; Cryopreservation And Storage Services
Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Charles River Laboratories International Inc.; Lonza Group AG; Catalent Inc.; WuXi AppTec; Takara Bio Inc.; Fujifilm Holdings Corporation; Oxford Biomedica plc; Cell and Gene Therapy Catapult; Samsung Biologics Co. Ltd.; BioNTech SE; Novartis International AG; Pfizer Inc.; Boehringer Ingelheim International GmbH; Sarepta Therapeutics Inc.; bluebird bio Inc.; Precision BioSciences Inc.; GSK plc; AstraZeneca plc; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell & Gene Therapy Manufacturing Services market report include:- Thermo Fisher Scientific Inc.
- Merck KGaA
- Charles River Laboratories International Inc.
- Lonza Group AG
- Catalent Inc.
- WuXi AppTec
- Takara Bio Inc.
- Fujifilm Holdings Corporation
- Oxford Biomedica plc
- Cell and Gene Therapy Catapult
- Samsung Biologics Co. Ltd.
- BioNTech SE
- Novartis International AG
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Sarepta Therapeutics Inc.
- bluebird bio Inc.
- Precision BioSciences Inc.
- GSK plc
- AstraZeneca plc
- Bayer AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.08 Billion |
| Forecasted Market Value ( USD | $ 21.05 Billion |
| Compound Annual Growth Rate | 17.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
